Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
Recruiting
N/A
Interventional Study
Non-alcoholic Fatty Liver Disease (NAFLD)
Alcoholic Liver Disease (ALD)
Liver Fibrosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 40 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 1,788 (estimated)
- Sponsor
- University Hospital, Angers · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* NAFLD and/or ALD patient defined by at least 1 of the following criteria:
* Excessive alcohol consumption: higher than 210 g / week (men), or 140 g / week (women)
* Type 2 diabetes
* at least 2 metabolic factors among BMI higher than or equal to 25 kg / m 2; Elevated bl…
Contacts